Blank Bio develops cell engineering technology to create therapeutic cells for treating diseases.
$7.2MSeed
Investor undisclosed
A $7.2M seed for cell engineering suggests investors are betting on the tooling layer, not just one-off therapies—this is about making cell manufacturing repeatable and cheaper. If you're in adjacent biotech (gene therapy, immunotherapy platforms), watch whether Blank Bio's approach becomes the standard for de-risking cell line development, because that directly affects your manufacturing timeline and unit economics.